Most cited papers from Springer Nature (New Zealand)
What are the most cited papers from Springer Nature (New Zealand)?
The most cited paper from Springer Nature (New Zealand) is "Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations" (Don Husereau, Michael Drummond, Federico Augustovski et al., 2022), with 1,117 citations. Next come "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force" (888) and "Patisiran: First Global Approval" (620).
Showing 50 of 56 papers. Every paper with more than 197 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations Don Husereau, Michael Drummond, Federico Augustovski et al. · Value in Health | 2022 | 1,117 |
| 2 | Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force Don Husereau, Michael Drummond, Federico Augustovski et al. · Value in Health | 2022 | 888 |
| 3 | Patisiran: First Global Approval Sheridan M. Hoy · Drugs | 24 Sep 2018 | 620 |
| 4 | BNT162b2 mRNA COVID-19 Vaccine: First Approval Yvette N. Lamb · Drugs | Mar 2021 | 437 |
| 5 | Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting Gillian M. Keating · Drugs | 10 Jun 2015 | 436 |
| 6 | Givosiran: First Approval Lesley J. Scott · Drugs | Feb 2020 | 423 |
| 7 | Tocilizumab: A Review in Rheumatoid Arthritis Lesley J. Scott · Drugs | Nov 2017 | 423 |
| 8 | Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections Matt Shirley · Drugs | Apr 2018 | 389 |
| 9 | Inclisiran: First Approval Yvette N. Lamb · Drugs | Feb 2021 | 361 |
| 10 | Resmetirom: First Approval Susan J. Keam · Drugs | 21 May 2024 | 354 |
| 11 | Tazemetostat: First Approval Sheridan M. Hoy · Drugs | 12 Mar 2020 | 344 |
| 12 | Onasemnogene Abeparvovec: First Global Approval Sheridan M. Hoy · Drugs | Jul 2019 | 344 |
| 13 | Lenvatinib: A Review in Hepatocellular Carcinoma Zaina T. Al-Salama, Yahiya Y. Syed, Lesley J. Scott · Drugs | Apr 2019 | 337 |
| 14 | Sorafenib: A Review in Hepatocellular Carcinoma Gillian M. Keating · Targeted Oncology | 15 Mar 2017 | 318 |
| 15 | Golodirsen: First Approval Young‐A Heo · Drugs | Feb 2020 | 317 |
| 16 | Osimertinib: First Global Approval Sarah L. Greig · Drugs | 4 Jan 2016 | 316 |
| 17 | Nirmatrelvir Plus Ritonavir: First Approval Yvette N. Lamb · Drugs | 19 Mar 2022 | 311 |
| 18 | Tofacitinib: A Review in Rheumatoid Arthritis Sohita Dhillon · Drugs | 14 Nov 2017 | 301 |
| 19 | Nusinersen: First Global Approval Sheridan M. Hoy · Drugs | 22 Feb 2017 | 298 |
| 20 | Lumasiran: First Approval Lesley J. Scott, Susan J. Keam · Drugs | 6 Jan 2021 | 297 |
| 21 | Sacituzumab Govitecan: First Approval Yahiya Y. Syed · Drugs | 11 Jun 2020 | 296 |
| 22 | Remdesivir: First Approval Yvette N. Lamb · Drugs | Sep 2020 | 294 |
| 23 | Aducanumab: First Approval Sohita Dhillon · Drugs | 29 Jul 2021 | 293 |
| 24 | Anlotinib: First Global Approval Yahiya Y. Syed · Drugs | 26 Jun 2018 | 291 |
| 25 | Casimersen: First Approval Matt Shirley · Drugs | 16 Apr 2021 | 286 |
| 26 | Alpelisib: First Global Approval Anthony Markham · Drugs | 29 Jun 2019 | 278 |
| 27 | Camrelizumab: First Global Approval Anthony Markham, Susan J. Keam · Drugs | 16 Jul 2019 | 274 |
| 28 | Trastuzumab Deruxtecan: First Approval Susan J. Keam · Drugs | 7 Mar 2020 | 273 |
| 29 | Roxadustat: First Global Approval Sohita Dhillon · Drugs | 25 Feb 2019 | 258 |
| 30 | Caplacizumab: First Global Approval Sean T. Duggan · Drugs | Oct 2018 | 253 |
| 31 | Pexidartinib: First Approval Yvette N. Lamb · Drugs | 10 Oct 2019 | 252 |
| 32 | Venetoclax: First Global Approval Emma D. Deeks · Drugs | Jun 2016 | 244 |
| 33 | Dapagliflozin: A Review in Type 2 Diabetes Sohita Dhillon · Drugs | 25 Jun 2019 | 242 |
| 34 | Pemigatinib: First Approval Sheridan M. Hoy · Drugs | 29 May 2020 | 241 |
| 35 | Larotrectinib: First Global Approval Lesley J. Scott · Drugs | 11 Jan 2019 | 241 |
| 36 | Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers Lesley J. Scott · Drugs | 16 Apr 2018 | 239 |
| 37 | Eteplirsen: First Global Approval Yahiya Y. Syed · Drugs | Nov 2016 | 232 |
| 38 | Sotorasib: First Approval Hannah A. Blair · Drugs | 6 Aug 2021 | 230 |
| 39 | Viltolarsen: First Approval Sohita Dhillon · Drugs | 9 Jun 2020 | 227 |
| 40 | Polatuzumab Vedotin: First Global Approval Emma D. Deeks · Drugs | 27 Jul 2019 | 223 |
| 41 | Volanesorsen: First Global Approval Julia Paik, Sean T. Duggan · Drugs | 12 Jul 2019 | 219 |
| 42 | Pitolisant: A Review in Narcolepsy with or without Cataplexy Yvette N. Lamb · CNS Drugs | 29 Jan 2020 | 217 |
| 43 | Baloxavir: First Global Approval Young‐A Heo · Drugs | Apr 2018 | 214 |
| 44 | Sintilimab: First Global Approval Sheridan M. Hoy · Drugs | Feb 2019 | 210 |
| 45 | Fexinidazole: First Global Approval Emma D. Deeks · Drugs | 11 Jan 2019 | 210 |
| 46 | Pretomanid: First Approval Susan J. Keam · Drugs | 3 Oct 2019 | 208 |
| 47 | Pyrotinib: First Global Approval Hannah A. Blair · Drugs | 19 Oct 2018 | 205 |
| 48 | Epi proColon® 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer Yvette N. Lamb, Sohita Dhillon · Molecular Diagnosis & Therapy | 2 Feb 2017 | 204 |
| 49 | Telitacicept: First Approval Sohita Dhillon · Drugs | 31 Aug 2021 | 202 |
| 50 | Talazoparib: First Global Approval Sheridan M. Hoy · Drugs | 30 Nov 2018 | 202 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.